Regadenoson
Who holds supplier records for Regadenoson? 11 organisations hold a current record for Regadenoson: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings. Recorded organisation countries for current records: India (6), Taiwan (1) and Switzerland (1); not recorded for 3.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Regadenoson: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/regadenoson
Reading the evidence
- 11 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
6 of the 8 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 5 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Regadenoson expires 2 Feb 2027. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (11)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Regadenoson. Country is the organisation's recorded country, not necessarily the manufacturing site.
- GLAND PHARMA LTDIndia Company GMP cert on recordActive DMF 27972, 37226 · latest filing Jun 2022
- BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITEDIndiaActive DMF 30834 · latest filing Sept 2016
- CURIA MISSOURI INCActive DMF 30542 · latest filing May 2016
- CZECH-GEN ASCompany GMP cert on recordActive DMF 35433 · latest filing Jan 2021
- MATRIX PHARMACORP PRIVATE LTDIndiaActive DMF 32339 · latest filing Jan 2018
- MSN LIFE SCIENCES PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 36338 · latest filing Nov 2021
- NANJING HERON PHARMACEUTICAL CO LTDActive DMF 36679 · latest filing Jan 2022
- SCINOPHARM TAIWAN LTDTaiwanActive DMF 28939 · latest filing Dec 2014
- Sun Pharmaceutical Industries LimitedIndia Company GMP cert on recordActive DMF 31539 · latest filing Nov 2017
- USV PRIVATE LTDIndia Company GMP cert on recordActive DMF 29315 · latest filing Jun 2015
- WOCKHARDT BIO AGSwitzerlandActive DMF 29185 · latest filing Mar 2015
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (1)
Organisations whose Type II DMFs for Regadenoson are no longer active. These show a past filing, not current supply.
Show all 1 historical record
- Czechia · Inactive DMF 25939 · filed Apr 2012
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (12 listed products contain Regadenoson). The latest listed patent expires 2 Feb 2027. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Regadenoson is a selective A2A adenosine receptor agonist used as a pharmacologic stress agent for myocardial perfusion imaging in patients unable to undergo adequate exercise stress. It is used clinically to help diagnose coronary artery disease via its ability to increase blood flow in the coronary vasculature.
Chemical identity
- IUPAC name
- 1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-N-methylpyrazole-4-carboxamide;hydrate
- Canonical SMILES
- CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N.O
- InChIKey
- CDQVVPUXSPZONN-WPPLYIOHSA-N
- Synonyms
- Lexiscan API, cvt-3146, lexiscan, rapiscan, regadenoson hydrate, regadenoson monohydrate
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Pharmacologic Cardiac Stress Test Agent
- Mechanism of action
- Adenosine Receptor Agonists
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Regadenoson?
11 organisations hold an active US FDA Type II Drug Master File or a CEP for Regadenoson: GLAND PHARMA LTD (India), BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India), CURIA MISSOURI INC, CZECH-GEN AS, MATRIX PHARMACORP PRIVATE LTD (India), MSN LIFE SCIENCES PRIVATE LIMITED (India), NANJING HERON PHARMACEUTICAL CO LTD and SCINOPHARM TAIWAN LTD (Taiwan), and 3 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Regadenoson Drug Master Files are active?
GLAND PHARMA LTD (DMF 27972, 37226), BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 30834), CURIA MISSOURI INC (DMF 30542), CZECH-GEN AS (DMF 35433), MATRIX PHARMACORP PRIVATE LTD (DMF 32339), MSN LIFE SCIENCES PRIVATE LIMITED (DMF 36338), NANJING HERON PHARMACEUTICAL CO LTD (DMF 36679) and SCINOPHARM TAIWAN LTD (DMF 28939) and 3 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Regadenoson records mean?
1 organisation has only inactive Type II DMFs for Regadenoson. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Regadenoson?
Yes. The latest patent listed for an approved US product containing Regadenoson expires 2 Feb 2027, across 12 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Regadenoson supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Regadenoson?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.